ArticleCHEST pulmonary2024
Oral Capsaicin as Treatment for Unexplained Chronic Cough and Airway Symptoms.
Article in CHEST pulmonary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04125563 (Influence on Cough and Airway Symptoms by Oral Capsaicin - a Phase 2, Randomised, Placebo-controlled Clinical Study in Patients With Chronic Idiopathic Cough), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influence on Cough and Airway Symptoms by Oral Capsaicin - a Phase 2, Randomised, Placebo-controlled Clinical Study in Patients With Chronic Idiopathic Cough
Who cites it
1 citing paper in PubMed.
- Increased Resistance of the Peripheral Airways in Patients with Unexplained Chronic Cough.Respiration; international review of thoracic diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Unexplained chronic cough (UCC) is characterized by persistent coughing without evident medical explanation. Research Question: Does daily oral administration of natural capsaicin (chili) improve refractory coughing in patients with UCC? Study Design and Methods: Forty-six patients (mean age, 60.5 years) with UCC participated in this crossover, randomized double-anonymized study. For 4 weeks, the participants took capsules containing pure capsaicin orally, and after a washout of 2 weeks, took placebo capsules for 4 weeks. A capsaicin inhalation cough test was used to assess the capsaicin inhalation concentration required to reach two coughs and the capsaicin inhalation concentration required to reach five coughs. The number of coughs in a 24-h period and the number of coughs per hour were recorded on four occasions using the Leicester Cough Monitor. Participants completed questionnaires with items on cough, cough-related symptoms, and quality of life. Results: The mean values for capsaicin inhalation concentration required to reach two coughs and the capsaicin inhalation concentration required to reach five coughs increased after the capsaicin treatment period as compared with the first visit (baseline; Interpretation: In this study, capsaicin powder taken orally was found to be clinically effective and well tolerated by patients with UCC. The results suggest a future treatment for UCC. Trial Registry: European Union Drug Regulating Authorities Clinical Trials Database; No.: EudraCT 2016-004463-39; URL: https://www.clinicaltrialsregister.euClinicalTrials.gov; No.: NCT04125563; URL: www.clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.